zunsemetinib
zunsemetinib: sourced relationships with 1 company · 2 clinical trials tracked.
zunsemetinib evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could zunsemetinib → ACRS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | Phase 2 |
Clinical Trial Registry Records (2)
Phase I Trial of MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Primary endpoint: Recommended phase II dose (RP2D) of zunsemetinib in combination with mFOLFIRINOX (Dose Escalation Only)
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Primary endpoint: Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12
Frequently asked questions
Which companies have sourced relationships with zunsemetinib?
zunsemetinib has dated SEC/FDA relationship records for Aclaris Therapeutics, Inc..
How many clinical trials involve zunsemetinib?
BioSniper tracks 2 clinical trials involving zunsemetinib.